Comparative Pharmacology
Head-to-head clinical analysis: EYSUVIS versus PRED MILD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EYSUVIS versus PRED MILD.
EYSUVIS vs PRED MILD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Eysuvis (loteprednol etabonate ophthalmic suspension) is a corticosteroid that works by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid and subsequent synthesis of prostaglandins and leukotrienes, thereby reducing inflammation.
Prednisolone acetate is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2 and reduction of inflammatory mediators such as prostaglandins and leukotrienes.
1 drop in each eye twice daily (approximately 12 hours apart) for 4 weeks.
1 to 2 drops in the affected eye(s) every hour during the day and every 2 hours at night until a favorable response is obtained, then reduce to 1 drop every 4 hours, and later to 1 drop 3 to 4 times daily as needed to control symptoms.
None Documented
None Documented
Approximately 2-4 hours for loteprednol etabonate; clinical effect correlates with dosing interval (e.g., 4 times daily).
The terminal elimination half-life of prednisolone is approximately 2.1-3.5 hours. Clinically, this short half-life supports once-daily dosing for many conditions, with minimal accumulation upon repeated administration.
Primarily renal (90-95% as unchanged drug and metabolites); minor biliary/fecal (<5%).
Prednisolone is primarily excreted renally, with approximately 70-80% of the dose eliminated as metabolites in urine (including glucuronides and sulfates) and less than 10% as unchanged drug. Biliary/fecal excretion accounts for about 20% of the dose.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid